Core Viewpoint - BofA believes that Novo Nordisk's announcement to reduce GLP-1 list prices is more of a headline grabber and will not significantly impact the U.S. market [1] Group 1: Novo Nordisk's Price Reduction - The price reduction is seen as an effort to lower copay and coinsurance costs for patients where these costs are based on list/WAC prices [1] - There is skepticism regarding the material impact of this move on the overall market dynamics for GLP-1 drugs [1] Group 2: Implications for Eli Lilly - BofA anticipates limited impact on Eli Lilly's GLP-1 franchise, as there is no clear indication that Novo Nordisk is aggressively lowering net prices in the commercial insurance channel [1] - The firm expects a greater contribution from cash pay and U.S. government channels, which are unaffected by Novo's price update [1] - BofA maintains a Buy rating on Eli Lilly, indicating confidence in its market position despite Novo's announcement [1]